Describe the safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia (BPD) and determine preliminary effectiveness and pharmacokinetics (PK) of sildenafil.
BPD is a common chronic lung disease that can affect premature newborns, often leading to life-long medical problems, prolonged hospitalization, and even death. Approximately 17,500 U.S. infants develop BPD each year.
Sildenafil, which is approved for the treatment of pulmonary hypertension in adults, may help improve lung development and is increasingly being used off-label in premature infants with BPD. However, the efficacy and safety of sildenafil in premature infants at risk for BPD is currently unknown.
Safety will be assessed following initial study-specific procedure (e.g., screening blood draws, dosing through 14 days post last study dose) and it will be assessed by frequency and incidence of adverse events and serious adverse events. The study team aims to enroll up to 120 participants.